JP2024500945A - ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 - Google Patents

ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 Download PDF

Info

Publication number
JP2024500945A
JP2024500945A JP2023538766A JP2023538766A JP2024500945A JP 2024500945 A JP2024500945 A JP 2024500945A JP 2023538766 A JP2023538766 A JP 2023538766A JP 2023538766 A JP2023538766 A JP 2023538766A JP 2024500945 A JP2024500945 A JP 2024500945A
Authority
JP
Japan
Prior art keywords
fcγriib
igg2
immunotherapeutic
protein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500945A5 (https=
Inventor
マーク ホガース，フィリップ
デイビッド ウィネス，ブルース
マリー トリスト，ハリナ
エリザベス エスパロン，サンドラ
ミシェル チェノウェス，アリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Genmab AS
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904823A external-priority patent/AU2020904823A0/en
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd, Genmab AS filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of JP2024500945A publication Critical patent/JP2024500945A/ja
Publication of JP2024500945A5 publication Critical patent/JP2024500945A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023538766A 2020-12-23 2021-12-22 ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 Pending JP2024500945A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904823 2020-10-22
AU2020904823A AU2020904823A0 (en) 2020-12-23 Modified immunoglobulin and method of use thereof (1)
PCT/AU2021/051548 WO2022133543A1 (en) 2020-12-23 2021-12-22 Modified immunoglobulin with affinity for fcgammariib and method of use thereof

Publications (2)

Publication Number Publication Date
JP2024500945A true JP2024500945A (ja) 2024-01-10
JP2024500945A5 JP2024500945A5 (https=) 2025-01-06

Family

ID=82156888

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538766A Pending JP2024500945A (ja) 2020-12-23 2021-12-22 ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法

Country Status (5)

Country Link
US (1) US20240018269A1 (https=)
EP (1) EP4267627A4 (https=)
JP (1) JP2024500945A (https=)
AU (1) AU2021408091A1 (https=)
WO (1) WO2022133543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065409A2 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
WO2022074206A1 (en) * 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360981A1 (en) * 2003-09-26 2018-12-20 Xencor, Inc. Novel immunoglobulin variants
EP2176298B1 (en) * 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
WO2017214452A1 (en) * 2016-06-08 2017-12-14 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CN113603780B (zh) * 2017-03-28 2022-07-01 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
WO2020069382A1 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020065409A2 (en) * 2018-09-28 2020-04-02 Lyvgen Biopharma Co., Ltd. Anti-cd40 binding molecules having engineered fc domains and therapeutic uses thereof
WO2022074206A1 (en) * 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR IMMUNOLOGY, vol. 45(15), JPN6025048097, 2008, pages 3926 - 3933, ISSN: 0005738238 *

Also Published As

Publication number Publication date
AU2021408091A1 (en) 2023-07-13
US20240018269A1 (en) 2024-01-18
EP4267627A4 (en) 2024-12-04
EP4267627A1 (en) 2023-11-01
WO2022133543A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
AU2023200891B2 (en) Novel anti-PD-1 antibodies
RU2764559C2 (ru) МУТАНТНЫЕ ВАРИАНТЫ Fc IgG1, ЛИШЕННЫЕ ЭФФЕКТОРНЫХ ФУНКЦИЙ
JP7486636B2 (ja) 抗ｍｓ４ａ４ａ抗体及びその使用方法
Crescioli et al. IgG4 characteristics and functions in cancer immunity
Davies et al. Human IgG4: a structural perspective
CN107614013B (zh) 结合lag-3的分子和其使用方法
Monteiro Role of IgA and IgA fc receptors in inflammation
US11732043B2 (en) Antibodies that modulate a biological activity expressed by a cell
JP2022513432A (ja) 免疫細胞活性化のための二重特異性抗体
CN107108748A (zh) SIRPα免疫球蛋白融合蛋白
US20210214434A1 (en) Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment
CA3145885A1 (en) Anti-ms4a4a antibodies and methods of use thereof
JP2020048562A (ja) 新規な抗−Ｆｃ−ガンマレセプタＩＩＢ抗体およびその使用
JP6522585B2 (ja) Ｃｘｃｒ５に対するモノクローナル抗体
JP2020535819A (ja) Ｃｄ３／ｃｄ３３二重特異性結合分子
JP2019535282A (ja) Ｇｉｔｒおよびｃｔｌａ−４に対する二重特異性ポリペプチド
US20240018269A1 (en) MODIFIED IMMUNOGLOBULIN WITH AFFINITY FOR FcGAMMARIIb AND METHOD OF USE THEREOF
TW202304986A (zh) 靶向cd22及cd79b的抗體
JP2024510291A (ja) 免疫疾患を治療するための二機能性分子
US20240025995A1 (en) Dual targeted immune regulating compositions
WO2018129714A1 (zh) 抗pd-1的单克隆抗体及其应用
TW202330026A (zh) 用於療法之抗btn3a活化抗體及il2促效劑之組合
US20220242962A1 (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
KR20260051101A (ko) 면역 체계를 조절하는 분자 및 그 용도
CN116888156A (zh) 非阻断性人ccr8结合剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125